AEterna Zentaris Regains Compliance with The Nasdaq Stock Market -- New York Minimum Bid Price Listing Requirement

QUEBEC CITY, April 27 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received a letter from the Nasdaq Stock Market notifying it that the closing price per share of the Company’s common stock was above the US$1.00 minimum bid price for 10 consecutive trading days and that, as a result, the Company has regained compliance with Marketplace Rule 5450(a)(1) (the minimum bid price rule) as of Friday, April 23, 2010.